• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by COMPASS Pathways Plc

    11/14/24 4:20:24 PM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CMPS alert in real time by email
    SC 13G/A 1 tm2427061d7_sc13ga.htm SC 13G/A

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G*

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2

    (Amendment No. 1)*

     

     

    COMPASS Pathways plc
    (Name of Issuer)
     
    American Depositary Shares, each representing one ordinary share, par value of £0.008 per share (the “Shares”)
    (Title of Class of Securities)
     
    20451W101
    (CUSIP Number)
     
    September 30, 2024
    (Date of Event Which Requires Filing of the Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    o Rule 13d-1(b)
    x Rule 13d-1(c)
    o Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    CUSIP No. 20451W101 13G Page 2 of 13 Pages

     

     

    1.

    NAME OF REPORTING PERSONS

     

    Citadel Advisors LLC

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)     o

    (b)     o

     

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    5,282,648 Shares

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    See Row 6 above

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    See Row 6 above

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    o

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    7.7%1

    12.

    TYPE OF REPORTING PERSON

     

    IA; OO; HC

           

     

    _________________________

    1 The percentages reported in this Schedule 13G are based upon 68,388,194 Shares outstanding as of July 29, 2024 (according to the issuer’s Form 10-Q as filed with the Securities and Exchange Commission on August 1, 2024).

     

     

     

     

    CUSIP No. 20451W101 13G Page 3 of 13 Pages

     

     

    1.

    NAME OF REPORTING PERSONS

     

    Citadel Advisors Holdings LP

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)     o

    (b)     o

     

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    5,282,648 Shares

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    See Row 6 above

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    See Row 6 above

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    o

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    7.7%

    12.

    TYPE OF REPORTING PERSON

     

    PN; HC

           

     

     

     

     

    CUSIP No. 20451W101 13G Page 4 of 13 Pages

     

     

    1.

    NAME OF REPORTING PERSONS

     

    Citadel GP LLC

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)     o

    (b)     o

     

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    5,282,648 Shares

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    See Row 6 above

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    See Row 6 above

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    o

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    7.7%

    12.

    TYPE OF REPORTING PERSON

     

    OO; HC

           

     

     

     

     

    CUSIP No. 20451W101 13G Page 5 of 13 Pages

     

     

    1.

    NAME OF REPORTING PERSONS

     

    Citadel Securities LLC

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)     o

    (b)     o

     

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    126,883 Shares

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    See Row 6 above

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    See Row 6 above

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    o

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.2%

    12.

    TYPE OF REPORTING PERSON

     

    BD; OO

           

     

     

     

     

    CUSIP No. 20451W101 13G Page 6 of 13 Pages

     

     

    1.

    NAME OF REPORTING PERSONS

     

    Citadel Securities Group LP

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)     o

    (b)     o

     

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    152,028 Shares

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    See Row 6 above

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    See Row 6 above

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    o

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.2%

    12.

    TYPE OF REPORTING PERSON

     

    PN; HC

           

     

     

     

     

    CUSIP No. 20451W101 13G Page 7 of 13 Pages

     

     

    1.

    NAME OF REPORTING PERSONS

     

    Citadel Securities GP LLC

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)     o

    (b)     o

     

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    152,028 Shares

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    See Row 6 above

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    See Row 6 above

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    o

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.2%

    12.

    TYPE OF REPORTING PERSON

     

    OO; HC

           

     

     

     

     

    CUSIP No. 20451W101 13G Page 8 of 13 Pages

     

     

    1.

    NAME OF REPORTING PERSONS

     

    Kenneth Griffin

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)     o

    (b)     o

     

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    U.S. Citizen

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    5,434,676 Shares

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    See Row 6 above

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    See Row 6 above

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    o

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    8.0%

    12.

    TYPE OF REPORTING PERSON

     

    IN; HC

           

     

     

     

     

    CUSIP No. 20451W101 13G Page 9 of 13 Pages

     

     

    Item 1(a). Name of Issuer:
       
      COMPASS Pathways plc
       
    Item 1(b). Address of Issuer’s Principal Executive Offices:
       
      33 Broadwick Street, London W1F 0DQ, United Kingdom 
       
    Item 2(a). Name of Person Filing:
       
      This Schedule 13G is being jointly filed by Citadel Advisors LLC (“Citadel Advisors”), Citadel Advisors Holdings LP (“CAH”), Citadel GP LLC (“CGP”), Citadel Securities LLC (“Citadel Securities”), Citadel Securities Group LP (“CALC4”), Citadel Securities GP LLC (“CSGP”) and Mr. Kenneth Griffin (collectively with Citadel Advisors, CAH, CGP, Citadel Securities, CALC4 and CSGP, the “Reporting Persons”) with respect to the Shares of the above-named issuer owned by Citadel Multi-Strategy Equities Master Fund Ltd., a Cayman Islands company (“CM”), Citadel CEMF Investments Ltd., a Cayman Islands limited company (“CCIL”), CRBU Holdings LLC, a Delaware limited liability company (“CRBH”), and Citadel Securities. Such owned Shares may include other instruments exercisable for or convertible into Shares.
       
      Citadel Advisors is the portfolio manager for CM and CCIL. CAH is the sole member of Citadel Advisors. CGP is the general partner of CAH. CALC4 is the non-member manager of CRBH and Citadel Securities.  CSGP is the general partner of CALC4.  Mr. Griffin is the President and Chief Executive Officer of CGP, and owns a controlling interest in CGP and CSGP.
       
      The filing of this statement shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any securities covered by the statement other than the securities actually owned by such person (if any).
       
    Item 2(b). Address or Principal Business Office or, if none, Residence:
       
      The address of each of the Reporting Persons is Southeast Financial Center, 200 S. Biscayne Blvd., Suite 3300, Miami, Florida 33131.
       
    Item 2(c). Citizenship:
       
      Each of Citadel Advisors, CGP, Citadel Securities and CSGP is organized as a limited liability company under the laws of the State of Delaware.  Each of CALC4 and CAH is organized as a limited partnership under the laws of the State of Delaware.  Mr. Griffin is a U.S. citizen.
       
    Item 2(d). Title of Class of Securities:
       
      American Depositary Shares, each representing one ordinary share, par value of £0.008 per share
       
    Item 2(e). CUSIP Number:
       
      20451W101

     

     

     

     

    CUSIP No. 20451W101 13G Page 10 of 13 Pages

     

     

    Item 3. If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:
       
      (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) ¨ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
      (f) ¨ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
      (g) ¨ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
      (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
      (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
      (j) ¨ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with § 240.13d-1(b)(1)(ii)(K).
             
      If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____________.
             
    Item 4. Ownership:
             
      A. Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC
             
        (a) Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may be deemed to beneficially own 5,282,648 Shares.
             
        (b) The number of Shares that each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may be deemed to beneficially own constitutes 7.7% of the Shares outstanding.
             
        (c) Number of Shares as to which such person has:
             
          (i) sole power to vote or to direct the vote:  0
             
          (ii) shared power to vote or to direct the vote:  5,282,648
             
          (iii) sole power to dispose or to direct the disposition of:  0
             
          (iv) shared power to dispose or to direct the disposition of:  5,282,648

     

     

     

     

    CUSIP No. 20451W101 13G Page 11 of 13 Pages

     

     

      B. Citadel Securities LLC
             
        (a) Citadel Securities LLC may be deemed to beneficially own 126,883 Shares.
           
        (b) The number of Shares that Citadel Securities LLC may be deemed to beneficially own constitutes 0.2% of the Shares outstanding.
           
        (c) Number of shares of Shares as to which such person has:
           
          (i) sole power to vote or to direct the vote:  0
             
          (ii) shared power to vote or to direct the vote:  126,883
             
          (iii) sole power to dispose or to direct the disposition of:  0
             
          (iv) shared power to dispose or to direct the disposition of:  126,883
             
      C. Citadel Securities Group LP and Citadel Securities GP LLC
             
        (a) Each of Citadel Securities Group LP and Citadel Securities GP LLC may be deemed to beneficially own 152,028 Shares.
           
        (b) The number of Shares that each of Citadel Securities Group LP and Citadel Securities GP LLC may be deemed to beneficially own constitutes 0.2% of the Shares outstanding.
           
        (c) Number of Shares as to which such person has:
           
          (i) sole power to vote or to direct the vote:  0
             
          (ii) shared power to vote or to direct the vote:  152,028
             
          (iii) sole power to dispose or to direct the disposition of:  0
             
          (iv) shared power to dispose or to direct the disposition of:  152,028
             

     

     

     

     

    CUSIP No. 20451W101 13G Page 12 of 13 Pages

     

     

      D. Kenneth Griffin
             
        (a) Mr. Griffin may be deemed to beneficially own 5,434,676 Shares.
           
        (b) The number of Shares that Mr. Griffin may be deemed to beneficially own constitutes 8.0% of the Shares outstanding.
           
        (c) Number of Shares as to which such person has:
           
          (i) sole power to vote or to direct the vote:  0
             
          (ii) shared power to vote or to direct the vote:  5,434,676
             
          (iii) sole power to dispose or to direct the disposition of:  0
             
          (iv) shared power to dispose or to direct the disposition of:  5,434,676

     

    Item 5. Ownership of Five Percent or Less of a Class:
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following. o
       
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person:
       
      Not Applicable
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:
       
      Not Applicable
       
    Item 8. Identification and Classification of Members of the Group:
       
      Not Applicable
       
    Item 9. Notice of Dissolution of Group:
       
      Not Applicable
       
    Item 10. Certifications:
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    CUSIP No. 20451W101 13G Page 13 of 13 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of its knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

     

    Dated November 14, 2024.

     

    CITADEL SECURITIES LLC   CITADEL ADVISORS LLC  
               
    By: /s/ Guy Miller   By: /s/ Seth Levy  
      Guy Miller, Authorized Signatory     Seth Levy, Authorized Signatory  
               
               
    CITADEL SECURITIES GROUP LP   CITADEL ADVISORS HOLDINGS LP  
               
    By: /s/ Guy Miller   By: /s/ Seth Levy  
      Guy Miller, Authorized Signatory     Seth Levy, Authorized Signatory  
               
               
    CITADEL SECURITIES GP LLC   CITADEL GP LLC  
               
    By: /s/ Guy Miller   By: /s/ Seth Levy  
      Guy Miller, Authorized Signatory     Seth Levy, Authorized Signatory  
               
               
          KENNETH GRIFFIN  
               
          By: /s/ Seth Levy  
            Seth Levy, attorney-in-fact*  

     

     

    _________________________

    * Seth Levy is signing on behalf of Kenneth Griffin as attorney-in-fact pursuant to a power of attorney previously filed with the Securities and Exchange Commission, and hereby incorporated by reference herein.  The power of attorney was filed as an attachment to a filing by Citadel Advisors LLC on Schedule 13G for Allakos Inc. on October 13, 2023.

     

     

     

    Get the next $CMPS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CMPS

    DatePrice TargetRatingAnalyst
    2/27/2025$11.00Buy
    Stifel
    7/23/2024$23.00Outperform
    RBC Capital Mkts
    4/1/2024$30.00Overweight
    Morgan Stanley
    12/12/2023$16.00Buy
    Deutsche Bank
    11/21/2022$33.00Buy
    Berenberg
    11/1/2022$34.00Buy
    Loop Capital
    11/22/2021$100.00 → $120.00Buy
    HC Wainwright & Co.
    10/29/2021$50.00Outperform
    Oppenheimer
    More analyst ratings

    $CMPS
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by COMPASS Pathways Plc

      SCHEDULE 13G - COMPASS Pathways plc (0001816590) (Subject)

      5/15/25 8:00:10 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • COMPASS Pathways Plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - COMPASS Pathways plc (0001816590) (Filer)

      5/8/25 6:39:09 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by COMPASS Pathways Plc

      10-Q - COMPASS Pathways plc (0001816590) (Filer)

      5/8/25 6:38:40 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CMPS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Medical Officer Goodwin Guy

      4 - COMPASS Pathways plc (0001816590) (Issuer)

      3/13/25 8:15:58 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Loxam Teri was granted 25,000 units of Ordinary Shares, increasing direct ownership by 43% to 83,250 units (SEC Form 4)

      4 - COMPASS Pathways plc (0001816590) (Issuer)

      3/13/25 8:15:29 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Nath Kabir was granted 92,000 units of Ordinary Shares, increasing direct ownership by 68% to 227,668 units (SEC Form 4)

      4 - COMPASS Pathways plc (0001816590) (Issuer)

      3/13/25 8:14:56 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CMPS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by COMPASS Pathways Plc

      SC 13G/A - COMPASS Pathways plc (0001816590) (Subject)

      11/14/24 4:35:16 PM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by COMPASS Pathways Plc

      SC 13G/A - COMPASS Pathways plc (0001816590) (Subject)

      11/14/24 4:20:24 PM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by COMPASS Pathways Plc

      SC 13G - COMPASS Pathways plc (0001816590) (Subject)

      4/11/24 4:04:21 PM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CMPS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Compass Pathways to Participate in 2025 RBC Capital Markets Global Healthcare Conference

      Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in a fireside chat at the 2025 RBC Capital Markets Global Healthcare Conference at 10:30 am ET on May 20th, 2025. A live audio webcast of the presentation will be accessible from the "Events" page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (NASDAQ:CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We

      5/14/25 6:30:00 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights

      Highlights: 6-week top-line data from Part A of COMP005 phase 3 trial in treatment resistant depression on track for late June Phase 3 COMP006 in TRD on track for 26-week data second half of 2026 Cash position of $260.1 million at March 31, 2025 Conference call on May 8 at 8:00 am ET (1:00 pm UK) Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the first quarter 2025 and provided an update on recent progress across its business. "We eagerly await the upcoming topline 6-week data readout, on track for late June, the first data from our pivotal

      5/8/25 6:30:00 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities

      Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into a strategic collaboration with HealthPort, a multi-site comprehensive community health organization. HealthPort employs an integrated model centered around social determinants of health and this collaboration will help inform the potential delivery of COMP360 synthesized psilocybin treatment in underserved communities, if FDA approved. This agreement with HealthPort expands the set of collaborations that Compass has established representing a broad spectrum of settings where people living with treatment resistant depression (TR

      4/29/25 6:30:00 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CMPS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Stifel initiated coverage on COMPASS Pathways with a new price target

      Stifel initiated coverage of COMPASS Pathways with a rating of Buy and set a new price target of $11.00

      2/27/25 6:17:48 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital Mkts initiated coverage on COMPASS Pathways with a new price target

      RBC Capital Mkts initiated coverage of COMPASS Pathways with a rating of Outperform and set a new price target of $23.00

      7/23/24 6:23:14 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morgan Stanley initiated coverage on COMPASS Pathways with a new price target

      Morgan Stanley initiated coverage of COMPASS Pathways with a rating of Overweight and set a new price target of $30.00

      4/1/24 7:29:23 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CMPS
    Leadership Updates

    Live Leadership Updates

    See more
    • Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities

      Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into a strategic collaboration with HealthPort, a multi-site comprehensive community health organization. HealthPort employs an integrated model centered around social determinants of health and this collaboration will help inform the potential delivery of COMP360 synthesized psilocybin treatment in underserved communities, if FDA approved. This agreement with HealthPort expands the set of collaborations that Compass has established representing a broad spectrum of settings where people living with treatment resistant depression (TR

      4/29/25 6:30:00 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Compass Pathways appoints Lori Englebert as Chief Commercial Officer

      New executive appointment made ahead of pivotal study results, potential regulatory approval and subsequent commercialization of investigational COMP360 psilocybin treatmentLatest of several key executive team hires, rounding out team to take Compass through phase 3 and beyond LONDON, June 26, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (NASDAQ:CMPS) ("Compass"), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today announced the appointment of Lori Englebert as Chief Commercial Officer, effective July 8, 2024. She will be based in the company's New York City office. Lori brings multifaceted experience in global ph

      6/26/24 6:30:00 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Compass Pathways appoints Teri Loxam as Chief Financial Officer

      LONDON, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (NASDAQ:CMPS) ("Compass"), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that it has appointed Teri Loxam as Chief Financial Officer (CFO), effective the beginning of March 2024. She will be based in the company's New York City office. Teri will serve as an advisor during the period leading up to her appointment as CFO.  Teri brings to Compass deep and extensive strategic experience working for publicly traded companies, in the pharmaceutical and biotechnology sectors, and beyond. She joins the company from Gameto, where she was CFO and played a

      12/7/23 7:00:00 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CMPS
    Financials

    Live finance-specific insights

    See more
    • Compass Pathways to Announce First Quarter Financial Results on May 8, 2025

      Compass management will host a conference call at 8:00 am ET (1:00 pm UK) Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the first quarter ended March 31, 2025, and provide an update on recent developments, on May 8, 2025. Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on May 8, 2025. A live webcast of the call will be available on the Compass Pathways website at: First Quarter 2025 Financial Results. The webcast will be archived for 30 days. About Compass Pathways Compass Pathways plc (NASDAQ:CMPS) is

      4/28/25 6:30:00 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025

      Compass management will host a conference call at 8:00 am ET (1:00pm UK) Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the fourth quarter 2024 ending December 31, 2024, and provide an update on recent developments, on February 27th, 2025. Compass management will host a conference call at 8:00 am ET (1:00pm UK) on February 27, 2025. To access the call, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on the Compass Pathways website at: F

      2/18/25 6:30:00 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Compass Pathways Announces Third Quarter 2024 Financial Results and Business Updates

      Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression now expected in second quarter 2025 COMP006 data will now be announced after 26-week time point, expected in the second half of 2026 Strategic reorganization to focus all efforts on COMP360 program resulting in reduction of workforce of approximately 30% Cash position of $207 million Conference call October 31 at 8:00 am ET (12:00 pm UK) Compass Pathways plc (NASDAQ:CMPS) ("Compass"), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today reported its financial results for the third quarter 2024 and an update on recent business progres

      10/31/24 6:30:00 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care